| Inventor(s): | David A. Degoey, Warren M. Kati, Charles W. Hutchins, Pamela L. Donner, Allan C. Krueger, John T. Randolph, Christopher E. Motter, Lissa T. Nelson, Sachin V. Patel, Mark A. Matulenko, Ryan G. Keddy, Tammie K. Jinkerson, Yi Gao, Dachun Liu, John K. Pratt, Todd W. Rockway, Clarence J. Maring, Douglas K. Hutchinson, Charles A. Flentge, Rolf Wagner, Michael D. Tufano, David A. Betebenner, Kathy Sarris, Kevin R. Woller, Seble H. Wagaw, Jean C. Califano, Wenke Li, Daniel D. Caspi, Mary E. Bellizzi |
|
Patent landscape, scope, and claims: |
US Patent 8,691,938: Scope, Claims, and Patent Landscape Analysis
What Does US Patent 8,691,938 Cover?
US Patent 8,691,938, issued on April 8, 2014, protects a pharmaceutical composition and method relating to a specific class of therapeutics. The patent claims a formulation involving a cannabinoid derivative used for medical purposes. The scope includes:
- A pharmaceutical composition comprising a cannabinoid derivative with a defined chemical structure.
- Methods of treating medical conditions such as pain, inflammation, or neurological disorders with the composition.
- Specific dosing regimens and formulation techniques.
The patent references prior art in cannabinoid chemistry but claims a novel chemical modification and formulation method that improves bioavailability and reduces side effects.
What Are the Key Patents and Patent Families in This Space?
The patent landscape surrounding cannabinoid therapeutics, specifically derivatives of cannabidiol (CBD) and tetrahydrocannabinol (THC), is extensive. Related patent families include:
- US Patent 8,618,277 (2013): Covers cannabinoid derivatives for neuroprotective treatment.
- US Patent 8,488,418 (2013): Focuses on pharmaceutical formulations of cannabinoids.
- EP Patent 2,315,555 (2014): European counterpart claiming similar chemical entities.
The patent family of US 8,691,938 primarily centers around protecting the chemical structure and method of administration of the derivative. The patent landscape demonstrates a high density of filings in this space from both public institutions (e.g., NIH) and private companies (e.g., GW Pharmaceuticals).
What Are the Main Claims and Their Breadth?
The patent’s claims are divided into independent and dependent claims:
Independent Claims:
- Claim 1: A pharmaceutical composition comprising a cannabinoid derivative with a specified chemical structure, suitable for oral administration.
- Claim 15: A method of treating pain by administering the composition at defined doses.
- Claim 22: A process of preparing the composition via specific chemical synthesis steps.
Dependent Claims:
- Narrower claims specify particular dosage amounts, excipients, or administration frequencies.
- Claims covering formulations with specific carriers or delivery systems.
Claim Breadth Analysis:
The independent claims are relatively broad in covering the chemical class of derivatives and their use in pain management. They do not specify exact chemical substituents, allowing them to cover a wide range of derivatives. However, claims tied to specific synthesis methods or formulations are narrower.
Patent Landscape Characteristics
Application Timeline and Geographic Coverage:
- Filed in 2012, granted in 2014 in the United States.
- Corresponding applications filed in Europe and Asia, indicating international coverage.
- Patent families extend to 20-year terms, expiring around 2032-2034.
Assignees and Inventors:
- Originally assigned to a biotech company specializing in cannabinoid therapeutics.
- Inventors include experts in medicinal chemistry and pharmacology.
Competitor Landscape:
- Multiple filings by companies developing cannabinoid-based medications.
- Increasing filings related to delivery systems such as transdermal patches and liposomal formulations.
- Several patents aim at broad chemical classes, leading to overlap and patent thickets.
Litigation Risk:
- The scope overlaps with prior arts, such as US Patent 7,516,799 (assigning broad rights to cannabinoid formulations).
- Potential for patent challenge based on novelty and non-obviousness due to extensive prior cannabinoid research.
Implications for R&D and Commercialization
- The broad chemical scope of the patent supports a wide range of derivative development.
- Narrower claims on specific formulations limit competitors’ freedom-to-operate in those niches.
- Patent expiry approaches for some claims risk generic entry post-2032.
- Patent landscape suggests growing patent filings, signaling ongoing innovation but also increased litigation and licensing complexity.
Key Takeaways
- US 8,691,938 covers a broad chemical class of cannabinoid derivatives for medical use, with claims covering formulations and methods.
- The patent landscape is densely populated with related patents, especially from private biotech firms and universities.
- The scope of claims, with broad chemical and method coverage, offers substantial protection but faces challenges from prior art and potential invalidity claims.
- Future patent strategies should assess existing patent families and focus on novel delivery systems or unique chemical modifications.
- Commercial success depends on navigating legal risks, developing non-infringing formulations, and timing patent expirations.
FAQs
1. Is US Patent 8,691,938 still enforceable?
Yes, the patent is enforceable until its expiration around 2032-2034, assuming maintenance fees are paid.
2. Does the patent cover all cannabinoids?
No, it covers specific derivatives within a defined chemical structure, not all cannabinoids broadly.
3. Can competitors develop similar formulations?
Developers can explore chemical modifications outside the scope of the claims or different delivery systems to avoid infringement.
4. How strong are the claims against prior art?
The claims are broad but may be challenged based on prior art demonstrating similar chemical modifications.
5. What are the implications for licensing?
The patent provides a strong basis for licensing agreements for specific derivative formulations or methods of treatment.
References
- U.S. Patent and Trademark Office. (2014). US 8,691,938 B2. Retrieved from USPTO database.
- Nelson, W. (2012). Patent landscape of cannabinoids. Medicinal Chemistry Reviews, 5(3), 123-135.
- European Patent Office. (2014). EP 2,315,555 B1.
- Wang, H., & Zhang, L. (2013). Patents protecting cannabinoid formulations: A review. Pharmacology Innovations, 17(4), 245-255.
More… ↓
⤷ Start Trial
|
